Depression is a complex disease in which a plethora of brain abnormalities are involved which can be at a structural, connectivity, and functional activation level, as Prof. Brenda Penninx (Amsterdam UMC, the Netherlands) explained [1,2,3]. Depression also involves dysregulated stress systems and disrupted energy regulation signalling, which may explain an association between depression and obesity [4,5]. Recent genome-wide analysis studies have provided insights into the genetic basis of depression [6]. When we combine all this data, there is more and more knowledge about the pathophysiology of depression. Combined evidence for the pathophysiology is now available based on numerous studies on:
- genome-wide single-nucleotide polymorphism (SNPs);
- smaller hippocampal volume and thinner cortical grey matter;
- higher cortisol;
- higher hsCRP and higher IL-6;
- insulin resistance;
- higher leptin;
- metabolic syndrome; and
- obesity [1,7].
Nonetheless, the effect sizes are small and the heterogeneity across the studies is large, as a result of methodological differences in trials. The heterogeneity of the disease itself also plays a role.
According to Prof. Penninx, the crucial next step is to gain more evidence on how to cluster more homogeneous patient groups –either based on symptoms or on neurobiology– which is the focus of personalised medicine. This raises the question of where to start; from known subtypes or data-based typing? Ideally, these results should be combined to gain the most convincing evidence.
A good example of a study aiming to better understand the heterogeneity of depression is NESDA, a naturalistic cohort study with 3,348 participants (66% female; age 18-65 years). Participants are recruited from the community, general practice, and mental health care and include healthy individuals, people with depression, people with anxiety disorders, and siblings of those people.
Data for the NESDA study was collected at baseline, and after 1, 2, 4, 6, and 9 years. In a NESDA substudy, 3 classes were characterised based on demographic, clinical psychiatric, psychosocial, and physical health descriptors: those with moderate depression (29.1%), those with severe typical depression (46.3%), and those with severe atypical depression (24.6%) [7]. Although those with severe atypical depression were more often female, they did not differ from the severe typical patients in age, duration, functioning, and comorbid anxieties. Based on symptomatology, patients were divided into 2 groups with “typical” or “atypical” depression (see Table) [7].
Table: Evidence for depression subtypes [7]

Interestingly, there were differences in cortisol and inflammatory markers between the groups. Other projects also confirmed these findings. There seems to be a different neurobiological basis for major depression disorder subtypes, and this should be followed up in larger studies (see Table). Moreover, these patients have an overlapping genetic basis with obesity and metabolic dysregulation genes [8]. This has implications for treatment choices and may necessitate anti-inflammatory treatment such as COX2 inhibitors.
Prof. Penninx concluded by stating that precision psychiatry is not easy but is the route of choice. “Large-scale deep-phenotyping research is needed to gain a better understanding of the heterogeneity of depression. In our research line, immunometabolic depression is characterised by atypical neurovegetative symptoms and immunometabolic dysregulation, and we hope to show that differentiating immunometabolic depression may be useful in clinical practice.” However, it is not the only relevant distinction; more research lines can further identify subgroups of patients. To unpack the heterogeneity of depression, it is necessary to extend the scale of research, move beyond one marker, and use deep-phenotyping approaches.
- Penninx B. Personalised medicine in depression; a realistic way forward? 05.01. ECNP Congress 2020.
- Palmer SM, et al. Front Hum Neurosci. 2014;8:1045.
- Kaiser RH, et al. JAMA Psychiatry. 2015 Jun;72(6):603-11.
- Otte C. Nat Rev Dis Primers. 2016 Sep 15;2:16065.
- Milaneschi Y, et al. Mol Psychiatry. 2019 Jan;24(1):18-33.
- Howard DM, et al. Nature Neuroscience. 2019;22:343–352.
- Milaneschi Y, et al. Biol Psychiatry. 2020;88(5):369-380.
- Lamers F, et al. J Clin Psych. 2010 Dec;71(12):1582-9.
Posted on
Previous Article
« Heart rate could be a potential biomarker for depression Next Article
rTMS is not effective in OCD »
« Heart rate could be a potential biomarker for depression Next Article
rTMS is not effective in OCD »
Table of Contents: ECNP 2020
Featured articles
Psychosis and Schizophrenia
Prognostic tools in the management of clinical high risk for psychosis
Reduced auditory cortex activation during speech perception in patients with schizophrenia
Dementia
Predicting MCI and dementia by assessing worrying about memory
Genomics of vascular dementia and stroke
Bipolar Disorders
Social media and bipolar disorder: a risky combination
How to prevent the onset and first relapse of bipolar disorders?
Seasonal pattern and bipolar disorder
OCD and Depression
Personalised medicine in depression: a realistic way forward?
Heart rate could be a potential biomarker for depression
Listening to Mozart has a beneficial effect on epilepsy
Mental Health
Mental health during the COVID-19 pandemic
Microdosing psychedelics offers perspective but needs further evaluation
The PRISM project: focusing on biological parameters across neuropsychiatric disorders
Smartphone can support personalised medicine in psychiatry
Baby’s heart rate shows stress if their mother is depressed or anxious
Autism and ADHD
Movement computing promising in analysing motor impairment in children with autism spectrum disorder
Screening with ADHD Self-Report accurate in girls
No altered fractional anisotropy in ADHD
Role of the Microbiome
Micronutrient supplementation as treatment for psychiatric symptoms
Substance Abuse
Altered gene expression of endogenous opioid system after alcohol exposure in adolescent rodents
Subgroups in alcohol use disorder based on externalising symptoms
New drugs for alcohol use disorder to focus on combination therapy
Related Articles
November 26, 2021
Finding biomarkers for improved patient stratification

November 2, 2020
How to prevent the onset and first relapse of bipolar disorders?
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com